Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618655 | 0.83 | CRBN (0.61) | CRBNDDB1HTR2CSMN1; SMN2MAPK1 | |
| SCHEMBL24251635 | 0.79 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1MEN1 | |
| SCHEMBL5192402 | 0.78 | LTA4H (0.61) | CRBNDDB1HTR2AHTR2CHTR2B | |
| SCHEMBL29098495 | 0.78 | ALDH1A1 (0.47) | CRBNDDB1HTR2CALDH1A1SMN1; SMN2 | |
| SCHEMBL16228472 | 0.77 | ALDH1A1 (0.49) | CRBNDDB1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL6431088 | 0.76 | MEN1 (0.48) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1MEN1 | |
| SCHEMBL6431426 | 0.76 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1MEN1 | |
| SCHEMBL3569051 | 0.76 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1MEN1 | |
| SCHEMBL25001507 | 0.76 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2MAPK1L3MBTL1MEN1 | |
| SCHEMBL6601404 | 0.75 | EGFR (0.54) | HTR2CALDH1A1SMN1; SMN2MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | X-RX, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2019-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233182-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, CXCR3, SLC10A1 | CRBN 3966/4885DDB1 3334/4885HTR2A 3258/4885 |
| US-20190225611-A1 | SUBSTITUTED SPIROCYCLIC INHIBITORS OF AUTOTAXIN | ENPP2, SLC10A1, CXCR3 | CRBN 3989/4885DDB1 3023/4885HTR2A 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.